CNTA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 9.09%

Insider Buying (Last 12 Months): $46,300.00

Insider Selling (Last 12 Months): $616,337.76

Centessa Pharmaceuticals Insider Trading History Chart

Centessa Pharmaceuticals Share Price & Price History

^$3.65

▼ -0.3 (-7.59%)

As of 03/22/2023 01:00 AM ET

Days: 30 | 90 | 365

The Safest Option in Trades!

From Tradewins | Ad

If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

Click here now!

Centessa Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/4/2023	Antoine Yver	EVP	Sell	6,970	$3.18	$22,164.60	751,913
12/1/2022	Antoine Yver	EVP	Sell	9,400	$3.91	$36,754.00	761,151
11/1/2022	Antoine Yver	EVP	Sell	9,700	$4.03	$39,091.00	765,059
10/3/2022	Antoine Yver	EVP	Sell	12,524	$3.92	$49,094.08	774,759
10/3/2022	David M Chao	Insider	Sell	4,167	$3.95	$16,459.65	222,932
10/3/2022	Gregory M Weinhoff	CFO	Sell	4,901	$3.95	$19,358.95	231,099
10/3/2022	Iqbal J Hussain	General Counsel	Sell	4,563	$3.95	$18,023.85	154,712
10/3/2022	Thomas Templeman	CTO	Sell	2,455	$3.95	$9,697.25	135,792
9/30/2022	Antoine Yver	EVP	Sell	2,468	$4.07	$10,044.76	787,283
9/30/2022	David M Chao	Insider	Sell	3,401	$4.07	$13,842.07	227,099
9/30/2022	Gregory M Weinhoff	CFO	Sell	4,000	$4.07	$16,280.00	236,000
9/30/2022	Iqbal J Hussain	General Counsel	Sell	3,725	$4.07	$15,160.75	159,275
9/30/2022	Thomas Templeman	CTO	Sell	2,003	$4.07	$8,152.21	138,247
8/1/2022	Antoine Yver	EVP	Sell	10,423	$4.45	$46,382.35	800,174
7/18/2022	Antoine Yver	EVP	Sell	20,000	$4.87	$97,400.00	810,597
7/1/2022	Antoine Yver	EVP	Sell	9,100	$5.03	$45,773.00	730,597
6/24/2022	Saurabh Saha	CEO	Buy	10,000	$4.63	$46,300.00	38,000
6/17/2022	Antoine Yver	EVP	Sell	9,200	$4.68	$43,056.00	739,697
5/17/2022	Antoine Yver	EVP	Sell	20,222	$5.42	$109,603.24	813,675
2/2/2022	Saurabh Saha	CEO	Buy	5,000	$9.74	$48,700.00
1/28/2022	David J. Grainger	Insider	Buy	27,500	$9.05	$248,875.00
12/2/2021	Medicxi Ventures Management (J	Major Shareholder	Buy	34,326	$12.82	$440,059.32
12/1/2021	Francesco De Rubertis	Director	Buy	60,304	$12.62	$761,036.48
11/30/2021	Medicxi Ventures Management (J	Major Shareholder	Buy	36,847	$11.62	$428,162.14
11/29/2021	Francesco De Rubertis	Director	Buy	56,706	$11.70	$663,460.20
11/26/2021	Francesco De Rubertis	Director	Buy	11,817	$11.34	$134,004.78
11/18/2021	Aaron Kantoff	Director	Buy	10,000	$11.98	$119,800.00
11/16/2021	Saurabh Saha	CEO	Buy	23,000	$12.28	$282,440.00
11/16/2021	Tia L. Bush	Insider	Buy	5,000	$12.46	$62,300.00

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

SEC Filings (Institutional Ownership Changes) for Centessa Pharmaceuticals (NASDAQ:CNTA)

78.03% of Centessa Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Centessa Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/15/2023	Jane Street Group LLC	25,985	$81K	0.0%	-13.1%	0.027%
2/15/2023	Tejara Capital Ltd	42,235	$0.13M	0.1%	N/A	0.045%
2/15/2023	Morgan Stanley	315,135	$0.98M	0.0%	+1,810.6%	0.333%
2/14/2023	Point72 Asset Management L.P.	79,700	$0.25M	0.0%	-32.3%	0.084%
2/14/2023	Price T Rowe Associates Inc. MD	2,387,167	$7.40M	0.0%	-2.4%	2.523%
2/14/2023	EcoR1 Capital LLC	5,232,279	$16.22M	0.5%	+61.7%	5.531%
2/13/2023	JPMorgan Chase & Co.	12,747	$39K	0.0%	+275.9%	0.013%
1/27/2023	Tanager Wealth Management LLP	1,878,383	$5.82M	1.6%	N/A	1.986%
11/16/2022	Jane Street Group LLC	29,911	$0.12M	0.0%	-24.0%	0.032%
11/15/2022	Price T Rowe Associates Inc. MD	2,445,983	$9.83M	0.0%	-0.6%	2.593%
11/15/2022	Kynam Capital Management LP	731,521	$2.94M	0.6%	-3.5%	0.775%
11/15/2022	EcoR1 Capital LLC	3,236,352	$13.01M	0.4%	+1,007.1%	3.431%
11/15/2022	Ensign Peak Advisors Inc	248,228	$1M	0.0%	+101.7%	0.263%
11/15/2022	BlackRock Inc.	293,511	$1.18M	0.0%	-2.8%	0.311%
11/15/2022	Citadel Advisors LLC	225,368	$0.91M	0.0%	-22.4%	0.239%
11/14/2022	Cormorant Asset Management LP	1,972,728	$7.93M	0.6%	-32.6%	2.091%
11/14/2022	Point72 Asset Management L.P.	117,800	$0.47M	0.0%	-11.8%	0.125%
8/18/2022	Goldman Sachs Group Inc.	16,543	$81K	0.0%	N/A	0.018%
8/16/2022	Jane Street Group LLC	39,335	$0.19M	0.0%	N/A	0.042%
8/16/2022	Woodline Partners LP	1,314,652	$6.40M	0.1%	+48.9%	1.398%
8/16/2022	Price T Rowe Associates Inc. MD	2,461,130	$11.99M	0.0%	-2.7%	2.617%
8/15/2022	Point72 Asset Management L.P.	133,600	$0.65M	0.0%	-85.3%	0.142%
8/15/2022	Citadel Advisors LLC	290,583	$1.42M	0.0%	-4.5%	0.309%
8/12/2022	Ensign Peak Advisors Inc	123,071	$0.60M	0.0%	-61.1%	0.131%
8/12/2022	Franklin Resources Inc.	832,932	$4.06M	0.0%	+35.0%	0.886%
8/11/2022	Alps Advisors Inc.	55,785	$0.27M	0.0%	N/A	0.059%
8/11/2022	JPMorgan Chase & Co.	178,414	$0.87M	0.0%	+3,683.2%	0.190%
8/4/2022	TD Asset Management Inc.	82,055	$0.40M	0.0%	+146.8%	0.087%
7/26/2022	Mirae Asset Global Investments Co. Ltd.	57,342	$0.70M	0.0%	N/A	0.061%
6/7/2022	Bank of America Corp DE	44,177	$0.40M	0.0%	-44.3%	0.047%
5/18/2022	Golden State Equity Partners	15,970	$0.14M	0.1%	+15.1%	0.017%
5/17/2022	Ensign Peak Advisors Inc	316,601	$2.84M	0.0%	-7.8%	0.337%
5/16/2022	Woodline Partners LP	882,633	$7.92M	0.1%	+10.2%	0.939%
5/16/2022	Prelude Capital Management LLC	11,400	$0.10M	0.0%	N/A	0.012%
5/13/2022	Affinity Asset Advisors LLC	65,282	$0.59M	0.1%	-84.4%	0.069%
5/13/2022	Kynam Capital Management LP	669,100	$6M	1.9%	+179.9%	0.712%
5/12/2022	BlackRock Inc.	276,518	$2.48M	0.0%	-3.7%	0.294%
5/4/2022	OUP Management Co. LLC	2,937,615	$26.35M	20.1%	+25.4%	3.124%
2/19/2022	Woodline Partners LP	801,136	$9.02M	0.1%	-9.3%	0.891%
2/15/2022	Samsara BioCapital LLC	1,459,693	$16.44M	3.2%	-5.1%	1.624%
2/14/2022	Virtus ETF Advisers LLC	14,798	$0.17M	0.1%	N/A	0.016%
2/14/2022	Boxer Capital LLC	1,251,137	$14.09M	0.5%	-6.2%	1.392%
2/14/2022	Point72 Asset Management L.P.	1,097,908	$12.36M	0.0%	+263.3%	1.221%
2/14/2022	Deep Track Capital LP	400,000	$4.50M	0.3%	N/A	0.445%
2/14/2022	Affinity Asset Advisors LLC	419,144	$4.72M	1.7%	+106.3%	0.466%
2/11/2022	Ensign Peak Advisors Inc	343,292	$3.87M	0.0%	+19.9%	0.382%
2/9/2022	Compagnie Lombard Odier SCmA	5,820	$66K	0.0%	+111.6%	0.006%
2/7/2022	American Century Companies Inc.	517,123	$5.82M	0.0%	+39.7%	0.575%
2/3/2022	OUP Management Co. LLC	2,341,891	$26.37M	11.9%	N/A	2.605%
2/3/2022	Medicxi Ventures Management Jersey Ltd	18,123,892	$204.08M	51.1%	+1.1%	20.160%
11/16/2021	Janus Henderson Group PLC	5,607,302	$91.36M	0.0%	-1.3%	6.237%
11/16/2021	Brookfield Asset Management Inc.	26,788	$0.45M	0.0%	+45.6%	0.030%
11/16/2021	Millennium Management LLC	337,002	$5.63M	0.0%	-38.6%	0.375%
11/16/2021	Boxer Capital LLC	1,334,227	$22.28M	0.8%	+47.6%	1.484%
11/16/2021	Citadel Advisors LLC	349,548	$5.84M	0.0%	-23.4%	0.389%
11/15/2021	Point72 Asset Management L.P.	302,200	$5.05M	0.0%	+202.2%	0.336%
11/15/2021	RA Capital Management L.P.	3,577,094	$59.74M	0.8%	+179.4%	3.979%
11/15/2021	General Atlantic L.P.	9,681,818	$161.69M	0.9%	+545.5%	10.770%
11/15/2021	Ensign Peak Advisors Inc	286,404	$4.78M	0.0%	-18.2%	0.319%
11/12/2021	Affinity Asset Advisors LLC	203,183	$3.39M	0.9%	+203.5%	0.226%
11/12/2021	Ghisallo Capital Management LLC	15,000	$0.25M	0.0%	-40.0%	0.017%
11/10/2021	American Century Companies Inc.	370,292	$6.18M	0.0%	-0.3%	0.412%
11/9/2021	Jennison Associates LLC	296,456	$4.95M	0.0%	-1.2%	0.330%
10/28/2021	Compagnie Lombard Odier SCmA	2,750	$46K	0.0%	N/A	0.003%
8/25/2021	Marshall Wace North America L.P.	34,228	$0.76M	0.0%	N/A	0.038%
8/18/2021	Blackstone Inc	40,000	$0.89M	0.0%	N/A	0.044%
8/17/2021	Woodline Partners LP	822,518	$18.27M	0.3%	N/A	0.915%
8/17/2021	Samsara BioCapital LLC	1,537,533	$34.15M	4.2%	N/A	1.710%
8/17/2021	Brookfield Asset Management Inc.	18,404	$0.41M	0.0%	N/A	0.020%
8/17/2021	Logos Global Management LP	939,545	$20.87M	1.8%	N/A	1.045%
8/17/2021	Millennium Management LLC	548,452	$12.18M	0.0%	N/A	0.610%
8/17/2021	Price T Rowe Associates Inc. MD	2,011,073	$43.86M	0.0%	N/A	2.237%
8/17/2021	BVF Inc. IL	58,900	$1.31M	0.0%	N/A	0.066%
8/17/2021	Boxer Capital LLC	904,227	$20.08M	0.7%	N/A	1.006%
8/17/2021	Caas Capital Management LP	62,500	$1.39M	0.0%	N/A	0.070%
8/17/2021	Citadel Advisors LLC	456,233	$10.13M	0.0%	N/A	0.507%
8/16/2021	Squarepoint Ops LLC	37,771	$0.84M	0.0%	N/A	0.042%
8/16/2021	Point72 Asset Management L.P.	100,000	$2.22M	0.0%	N/A	0.111%
8/16/2021	Blackstone Inc	40,000	$0.89M	0.0%	N/A	0.044%
8/16/2021	RA Capital Management L.P.	1,280,300	$28.44M	0.5%	N/A	1.424%
8/16/2021	Tudor Investment Corp Et Al	43,079	$0.96M	0.0%	N/A	0.048%
8/16/2021	Avoro Capital Advisors LLC	500,000	$11.11M	0.2%	N/A	0.556%
8/13/2021	General Atlantic L.P.	1,500,000	$33.32M	0.2%	N/A	1.669%
8/13/2021	VR Adviser LLC	1,127,272	$25.04M	3.0%	N/A	1.254%
8/13/2021	Northern Trust Corp	18,400	$0.41M	0.0%	N/A	0.020%
8/13/2021	Affinity Asset Advisors LLC	66,957	$1.49M	0.5%	N/A	0.074%
8/13/2021	Franklin Resources Inc.	922,700	$20.49M	0.0%	N/A	1.026%
8/13/2021	Ensign Peak Advisors Inc	350,000	$7.77M	0.0%	N/A	0.389%
8/13/2021	Geode Capital Management LLC	9,513	$0.21M	0.0%	N/A	0.011%
8/13/2021	FMR LLC	790,000	$17.55M	0.0%	N/A	0.879%
8/12/2021	Vida Ventures Advisors LLC	3,931,818	$87.33M	21.9%	N/A	4.374%
8/12/2021	State of Wisconsin Investment Board	80,381	$1.79M	0.0%	N/A	0.089%
8/12/2021	JPMorgan Chase & Co.	2,090	$47K	0.0%	N/A	0.002%
8/12/2021	Jennison Associates LLC	300,000	$6.66M	0.0%	N/A	0.334%
8/12/2021	Monashee Investment Management LLC	130,000	$2.89M	0.3%	N/A	0.145%
8/5/2021	American Century Companies Inc.	371,504	$8.25M	0.0%	N/A	0.413%

Data available starting January 2016

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Today's Range

Now: $3.65

$3.64

$3.99

50 Day Range

MA: $3.67

$3.03

$4.00

52 Week Range

Now: $3.65

$2.88

$9.95

Volume

17,346 shs

Average Volume

171,477 shs

Market Capitalization

$345.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Who are the company insiders with the largest holdings of Centessa Pharmaceuticals?: Centessa Pharmaceuticals' top insider shareholders include:
Antoine Yver (EVP)
Gregory M Weinhoff (CFO)
David M Chao (Insider)
Iqbal J Hussain (General Counsel)
Thomas Templeman (CTO)
Saurabh Saha (CEO)
(Bermuda) Ltd Gap (Major Shareholder)
Aaron Kantoff (Director)
David J Grainger (Insider)
Medicxi Ventures Management (J (Major Shareholder)
Rubertis Francesco De (Director)
Tia L Bush (Insider)
Learn More about top insider investors at Centessa Pharmaceuticals.
Who are the major institutional investors of Centessa Pharmaceuticals?: Centessa Pharmaceuticals' top institutional investors include:
EcoR1 Capital LLC — 5.53%
Price T Rowe Associates Inc. MD — 2.52%
Tanager Wealth Management LLP — 1.99%
Morgan Stanley — 0.33%
Point72 Asset Management L.P. — 0.08%
Tejara Capital Ltd — 0.04%
Learn More about top institutional investors of Centessa Pharmaceuticals stock.
Which institutional investors are selling Centessa Pharmaceuticals stock?: Within the previous quarter, CNTA stock was sold by these institutional investors:
Price T Rowe Associates Inc. MD
Point72 Asset Management L.P.
Jane Street Group LLC
During the previous year, company insiders that have sold Centessa Pharmaceuticals company stock include:
Antoine Yver (EVP)
Gregory M Weinhoff (CFO)
David M Chao (Insider)
Iqbal J Hussain (General Counsel)
Thomas Templeman (CTO)
Learn More investors selling Centessa Pharmaceuticals stock.
Which institutional investors are buying Centessa Pharmaceuticals stock?: Within the previous quarter, CNTA stock was purchased by institutional investors including:
EcoR1 Capital LLC
Tanager Wealth Management LLP
Morgan Stanley
Tejara Capital Ltd
JPMorgan Chase & Co.
In the previous year, these company insiders have bought Centessa Pharmaceuticals stock:
Antoine Yver (EVP)
Gregory M Weinhoff (CFO)
David M Chao (Insider)
Iqbal J Hussain (General Counsel)
Thomas Templeman (CTO)
Saurabh Saha (CEO)
(Bermuda) Ltd Gap (Major Shareholder)
Learn More investors buying Centessa Pharmaceuticals stock.

The 1 Stock To Watch In This Market.

From Upexi, Inc | Ad

This NASDAQ Stock Has Been On The Move In 2023 And It Looks Like Its Far From Over!